Outcomes and Prognostic Analysis of Surgical Resection for Oligometastasis from Hepatocellular Carcinoma
Anticancer Research 43 巻 11 号
5189-5196 頁
2023-11-01 発行
アクセス数 : 14 件
ダウンロード数 : 11 件
今月のアクセス数 : 3 件
今月のダウンロード数 : 3 件
この文献の参照には次のURLをご利用ください : https://ir.lib.hiroshima-u.ac.jp/00056130
| ファイル情報(添付) | |
| タイトル ( eng ) |
Outcomes and Prognostic Analysis of Surgical Resection for Oligometastasis from Hepatocellular Carcinoma
|
| 作成者 |
OSHITA KO
TADOKORO TAKESHI
NAMBA YOSUKE
FUKUHARA SOTARO
MATSUBARA KEISO
TAKEI DAISUKE
KURODA SHINTARO
|
| 収録物名 |
Anticancer Research
|
| 巻 | 43 |
| 号 | 11 |
| 開始ページ | 5189 |
| 終了ページ | 5196 |
| 抄録 |
Background/Aim: This study aimed to evaluate the outcomes of patients who underwent resection for oligometastasis from hepatocellular carcinoma (HCC) and identify the prognostic factors associated with poor survival. Patients and Methods: Patients who underwent resection for oligometastasis from HCC between January 2000 and April 2021 were retrospectively investigated. Oligometastasis was defined as 1-5 single organ metastases that were detected preoperatively in this study. Clinical characteristics and treatment outcomes were analyzed, and independent risk factors for poor prognosis were identified using cox proportional hazards model. Results: A total of 33 patients were included in this study. Eleven oligometastases were located in the intraabdominal lymph node, 8 in the adrenal gland, 5 in the lung, 4 in the peritoneum, 3 in the pleura, and 1 each in the supraclavicular lymph node and abdominal wall. No re-operation or operative death occurred in this study. The median OS was 44.6 months (range=5.1-150.6 months), and the median survival after primary HCC diagnosis was 116.5 months (range=7.1-253.6 months). The median cumulative incidence of recurrent HCC was 7.2 months (range=0.3-94.7 months). The multivariate analysis showed that an alpha-fetoprotein level ≥20 ng/ml and multiple primary HCC tumors were independent poor prognostic factors. Conclusion: Clinical characteristics and treatment outcomes of patients who underwent resection for oligometastasis from HCC were demonstrated. A high alpha-fetoprotein level and multiple primary HCC tumors were independent poor prognostic factors. Surgical resection can be one of the treatment options for oligometastasis from HCC.
|
| 著者キーワード |
Hepatocellular carcinoma
oligometastasis
surgical resection
|
| 言語 |
英語
|
| 資源タイプ | 学術雑誌論文 |
| 出版者 |
International Institute of Anticancer Research
|
| 発行日 | 2023-11-01 |
| 権利情報 |
Copyright © 2023 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
This is not the published version. Please cite only the published version.
この論文は出版社版ではありません。引用の際には出版社版をご確認、ご利用ください。
|
| 出版タイプ | Accepted Manuscript（出版雑誌の一論文として受付されたもの。内容とレイアウトは出版社の投稿様式に沿ったもの） |
| アクセス権 | オープンアクセス |
| 収録物識別子 |
[DOI] https://doi.org/10.21873/anticanres.16720
～の異版である
|
| 助成機関名 |
日本医療研究開発機構
Japan Agency for Medical Research and Development (AMED)
|
| 助成機関識別子 |
[Crossref Funder] https://doi.org/10.13039/100009619
|
| 研究課題名 |
分化制御NK細胞を用いた免疫療法による新規肝炎/肝癌治療の開発研究
分化制御NK細胞を用いた免疫療法による新規肝炎/肝癌治療の開発研究
|
| 研究課題番号 |
JP22fk0210108
|
